Every year, pharmaceutical companies lose an eye-watering $637bn through medication non-adherence – so why isn’t the industry taking this money-eating bull by the horns?
All too often pharmaceutical marketing orthodoxy says to focus on just one area – a product’s launch, in the belief that this is the only area that can determine success.
Ahead of the 2019 eyeforpharma Barcelona conference, we asked speaker Pol Vandenbroucke – chief medical officer of the Hospital Business Unit at Pfizer – for his view